focus -WSS

focus

author：hotspot 2025-10-04 11:35:47 - browse：2943

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

focus

WSS

World's first CRISPR

Surge of respiratory disease in China has likely explanation

Commercial surrogacy can be ethical, despite pope’s claims

Juul spent big to court Black leaders to promote its e

Congressmen charge Covid hearing ‘could have been an email’

Vertigo drug brings hope for rare neuron disorder, Niemann

entertainment

focus

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

ChatGPT in medicine: STAT answers readers' burning questions

Do digital therapeutics have a future in medicine?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ransomware attacks on hospitals: Study outlines patient impact

Dobbs anniversary: the lost opportunity of abortion as health care

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Medical leaders decry Supreme Court decision on affirmative action

Gain of function research would be limited under House proposal

focus

Congressmen charge Covid hearing ‘could have been an email’

In key trial, Verve's treatment lowers cholesterol levels in patients

World's first CRISPR

FDA's Woodcock to retire early next year

Poor hospice wound care hurts patients and families

CRISPR pioneers react to Casgevy, first gene

knowledge

focus

knowledge

focus